undamentalytics Newsletter
Sign in

Bionano Genomics, Inc. balance sheet

At the end of fiscal 2025, Bionano Genomics, Inc. had total assets of $73.6m, total liabilities of $29.2m and shareholders' equity of $44.4m. It held $3.0m in cash against $0 of debt: net cash of $3.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents117173825518934
Receivables3563579554
Inventory21331230281387
Total current assets7232847272157140394525
Goodwill——0756770———
Total assets10253060377308214777448
Accounts payable2133111310765
Deferred revenue (current)0000111111
Total current liabilities1752692236100372310
Short-term debt70200——————
Long-term debt090160—————
Total debt7102218000000
Total liabilities171527254058118412916
Shareholders' equity−501043533724996354432
Non-controlling interests and other (assets − liabilities − equity)43—————————
Net debt (negative = net cash)6−75−21−25−5−18−9−3−4
Shares outstanding———190m—446m———12m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BNGO vs MXCTBNGO vs RPIDBNGO vs OABI

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionano Genomics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionano Genomics, Inc.